Clinical Trial Update: BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy [Phase 3]

View source ↗

Summary

Anthera Pharmaceuticals has withdrawn the Phase 3 BRILLIANT-SC trial evaluating blisibimod for IgA nephropathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• blisibimod (blisibimod)

Snippet

Sponsor: Anthera Pharmaceuticals | Conditions: IgA Nephropathy | Phase 3 | Status: WITHDRAWN